tiprankstipranks
Advertisement
Advertisement

AKBA Stock Latest News

Akebia doses first participants in AKB-9090 trial
The FlyAkebia doses first participants in AKB-9090 trial
13d ago
AKBA
Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside
PremiumRatings
Akebia (AKBA): Buy Rating Backed by Vafseo Momentum and High-Value Renal Pipeline Upside
19d ago
AKBA
Akebia Therapeutics Earnings Call: Vafseo Drives Growth
PremiumCompany Announcements
Akebia Therapeutics Earnings Call: Vafseo Drives Growth
2M ago
AKBA
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today with 125%+ Upside, 2/27/2026, According to Top Analysts
2M ago
AKBA
BDSX
Akebia reports Q4 EPS (5c), consensus (4c)
PremiumThe Fly
Akebia reports Q4 EPS (5c), consensus (4c)
2M ago
AKBA
Akebia price target lowered to $4 from $5 at BTIG
PremiumThe FlyAkebia price target lowered to $4 from $5 at BTIG
2M ago
AKBA
Akebia Therapeutics (AKBA) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Akebia Therapeutics (AKBA) Q4 Earnings Cheat Sheet
2M ago
AKBA
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
Premium
Company Announcements
Akebia’s Praliciguat FSGS Trial Moves Forward, Adding Optionality to the Kidney Pipeline
2M ago
AKBA
Akebia price target lowered to $4 from $6 at Piper Sandler
PremiumThe Fly
Akebia price target lowered to $4 from $6 at Piper Sandler
3M ago
AKBA
Akebia Therapeutics Updates Executive Severance and Leadership Terms
PremiumCompany Announcements
Akebia Therapeutics Updates Executive Severance and Leadership Terms
3M ago
8K
AKBA
Akebia announces corporate updates, 2026 pipeline outlook
PremiumThe Fly
Akebia announces corporate updates, 2026 pipeline outlook
3M ago
AKBA
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
PremiumCompany Announcements
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline
3M ago
8K
AKBA
Akebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
PremiumRatingsAkebia Therapeutics: Advancing Praliciguat in FSGS and Vafseo Commercial Ramp Support Compelling Buy Thesis
4M ago
AKBA
Akebia announces first patient dosed in Phase 2 trial of praliciguat
Premium
The Fly
Akebia announces first patient dosed in Phase 2 trial of praliciguat
4M ago
AKBA
Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
Premium
Ratings
Strategic Expansion and Market Potential Drive Buy Rating for Akebia Therapeutics
5M ago
AKBA
Akebia Therapeutics Acquires Global Rights to ADX-097
PremiumCompany Announcements
Akebia Therapeutics Acquires Global Rights to ADX-097
5M ago
8K
AKBA
Akebia Therapeutics announces establishment of rare kidney disease pipeline
PremiumThe Fly
Akebia Therapeutics announces establishment of rare kidney disease pipeline
5M ago
AKBA
QTTB
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
PremiumThe Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront
5M ago
AKBA
QTTB
Q32 Bio sells complement inhibitor ADX-097 to Akebia
PremiumThe Fly
Q32 Bio sells complement inhibitor ADX-097 to Akebia
5M ago
AKBA
QTTB
Akebia Therapeutics Amends License Agreement with MEDICE
PremiumCompany AnnouncementsAkebia Therapeutics Amends License Agreement with MEDICE
5M ago
8K
AKBA
Akebia Therapeutics’ Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Akebia Therapeutics’ Earnings Call: Growth Amid Challenges
6M ago
AKBA
Akebia Therapeutics Reports Strong Q3 2025 Growth
Premium
Company Announcements
Akebia Therapeutics Reports Strong Q3 2025 Growth
6M ago
AKBA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >